Viewing Study NCT05777109



Ignite Creation Date: 2024-05-06 @ 6:46 PM
Last Modification Date: 2024-10-26 @ 2:54 PM
Study NCT ID: NCT05777109
Status: RECRUITING
Last Update Posted: 2023-08-23
First Post: 2023-03-08

Brief Title: Comparing of the PK PD Safety and Immunogenicity of HS-20090 and Xgeva in Healthy Adults
Sponsor: Jiangsu Hansoh Pharmaceutical Co Ltd
Organization: Jiangsu Hansoh Pharmaceutical Co Ltd

Study Overview

Official Title: A Dual-center Randomized Double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic Pharmacodynamics Safety and Immunogenicity of HS-20090 Injection and Xgeva in Healthy Adults
Status: RECRUITING
Status Verified Date: 2023-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A Dual-center Randomized double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic pharmacodynamics Safety and Immunogenicity of HS-20090 Injection and Xgeva in Healthy Adults
Detailed Description: This is a phase I dual-center randomized double-blind and parallel group clinical trial

The primary objective is to assess the pharmacokinetic similarity of single subcutaneously injection of HS-20090 or Xgeva in healthy volunteers

The secondary objectives are to assess the Clinical safety and immunogenicity similarity of single subcutaneously injection of HS-20090 or Xgeva in healthy volunteers Meanwhile observing the pharmacodynamic similarity of HS-20090 to Xgeva preliminarily

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None